Implications of EGFR PharmDx™ Kit for cetuximab eligibility

Expert Review of Molecular Diagnostics

Volumn 8, Issue 2, 2008, Pages 141-148

  Ensinger, Christian ^a   Sterlacci, William ^a  

^a MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cancer; Cetuximab; EGF receptor; EGFR; EGFR PharmDx kit; Immunohistochemistry; Monoclonal antibody; Targeted therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; PERTUZUMAB; TRASTUZUMAB;

BREAST CARCINOMA; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; REAGENT KITS, DIAGNOSTIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41549118120     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.2.141     Document Type: Review

References (111)

1. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1(5), 511-529 (1983).
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20(18 Suppl.), S1-S13 (2002). • John Mendelsohn, the initiator of EGF receptor (EGFR) targeting, giving the David A Karnowsky Award Lecture.
3. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA 80(5), 1337-1341 (1983) .
4. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Nat. Cancer Inst. 95(12), 851-867 (2003).
5. de Bono JS, Rowinsky EK. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. 64, 227-254 (2002).
6. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60(Suppl. 1), 25-32; discussion 41-22 (2000).
7. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol. 13(6), 491-498 (2001).
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
9. Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr. Drug Metab. 8(6), 554-562 (2007).
10. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin. Chem. Lab. Med. 45(7), 801-814 (2007).
11. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 8(2), 177-185 (2007).
12. Jain KK. Challenges of drug discovery for personalized medicine. Curr. Opin. Mol. Ther. 8(6), 487-492 (2006).
13. Carpenter G, Cohen S. Epidermal growth factor. J. Biol. Chem. 265(14), 7709-7712 (1990).
14. Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730), 1132-1139 (1985).
15. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4(1), 1-24 (1992).
16. Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29(50), 11024-11028 (1990).
17. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47(1), 87-98 (1991).
18. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20(10), 408-412 (1999).
19. Marti U, Burwen SJ, Jones AL. Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: an update. Hepatology 9(1), 126-138 (1989).
20. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995).
21. Wells A. The epidermal growth factor receptor and its ligands. Cancer Treat. Res. 47, 143-168 (1989).
22. Marti U, Ruchti C, Kampf J et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11(2), 137-145 (2001).
23. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5), 1593-1611 (2002). • Basics for development of EGFR targeting therapies.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. 2(2), 127-137 (2001) .
25. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), S9-S15 (2001).
26. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 17(3), 259-269 (1999).
27. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25-79 (2000).
28. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 30(1), 1-17 (2004).
29. Eccles SA, Modjtahedi H, Box G, Court W, Sandle J, Dean CJ. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14(1-6), 337-348 (1994).
30. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82(2-3), 241-250 (1999).
31. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA. Growth factor-induced cell motility in tumor invasion. Acta Oncol. 41(2), 124-130 (2002).
32. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8 (2001).
33. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13(12), 1501-1512 (1999).
34. Rodeck U, Jost M, Kari C et al. EGF-R dependent regulation of keratinocyte survival. J. Cell Sci. 110(Pt 2), 113-121 (1997).
35. Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J. Pathol. 179(3), 232-237 (1996).
36. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16(4), 750-759 (1997).
37. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J. Pathol. 184(1), 53-57 (1998).
38. Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. J. Cancer 32A(11), 1977-1982 (1996).
39. Shibata T, Kawano T, Nagayasu H et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. 17(3), 168-175 (1996).
40. Di Fiore PP, Pierce JH, Fleming TP et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51(6), 1063-1070 (1987).
41. McKay JA, Murray LJ, Curran S et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer 38(17), 2258-2264 (2002).
42. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 37(3), 285-289 (1998).
43. Nicholson S, Richard J, Sainsbury C et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer 63(1), 146-150 (1991).
44. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 50(21), 7077-7080 (1990).
45. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65(7), 1619-1625 (1990).
46. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78(6), 1284-1292 (1996).
47. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
48. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989).
49. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J. Clin. Oncol. 15(8), 2894-2904 (1997).
50. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol. 11(10), 1936-1942 (1993).
51. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737-744 (1996).
52. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999).
53. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Annals Pharmacother. 40(2), 241-250 (2006).
54. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
55. Ennis BW, Valverius EM, Bates SE et al. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol. Endocrinol. 3(11), 1830-1838 (1989).
56. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6(5), 1936-1948 (2000).
57. Divgi CR, Welt S, Kris M et al. Phase I and imaging trial of indium 111-labeled antiepidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Nat. Cancer Inst. 83(2), 97-104 (1991).
58. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther. 1(4), 719-732 (2001).
59. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5(2), 257-265 (1999).
60. Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25(29), 4557-4561 (2007).
61. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8(5), 994-1003 (2002).
62. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
63. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
64. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005).
65. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007).
66. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
67. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25(16), 2191-2197 (2007).
68. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 25(26), 4057-4065 (2007).
69. Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A. Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. Int. J. Biol. Markers 22(1 Suppl. 4), S10-S23 (2007).
70. Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 38(Suppl. 4), 43-49 (2002).
71. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int. J. Radiat. Oncol. Biol. Phys. 68(3), 873-882 (2007).
72. Wu G, Yang W, Barth RF et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4), 1260-1268 (2007).
73. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2), 127-137 (2002).
74. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003).
75. Shoji F, Yano T, Yoshino I et al. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. Eur. J. Surg. Oncol. (2007) (In press).
76. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21(12), 2237-2246 (2003).
77. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
78. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58(1), 95-103 (2007).
79. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
80. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
81. Lynch TJ, Adjei AA, Bunn PA Jr et al. Novel agents in the treatment of lung cancer: conference summary statement. Clin. Cancer Res. 10(12 Pt 2), S4199-S4204 (2004).
82. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
83. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
84. Reck M. Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future Oncol. 2(1), 47-51 (2006).
85. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23(31), 8081-8092 (2005).
86. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
87. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23(11), 2556-2568 (2005).
88. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
89. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
90. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23(11), 2445-2459 (2005). •• Comprehensive review on current therapeutic EGFR targeting.
91. Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov. Today 10(11), 781-788 (2005). • Future aspects of combinatorial biomarkers and their impact on cancer treatment.
92. Inoue A, Nukiwa T. Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med. 2(1), e13 (2005).
93. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Cell. Physiol. 205(3), 355-363 (2005).
94. Clark J, Cools J, Gilliland DG. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med. 2(3), E75 (2005).
95. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23(11), 2513-2520 (2005).
96. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9(5), 553-562 (1991).
97. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Iinvest. 95(4), 1897-1905 (1995).
98. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57(21), 4838-4848 (1997).
99. Azemar M, Schmidt M, Arlt F et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int. J. Cancer 86(2), 269-275 (2000).
100. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766(1), 120-139 (2006). • Comprehensive review dealing with aspects of EGFR targeting.
101. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
102. Ferrara J. Personalized medicine: challenges in assessing and capturing value in the commercial environment. Expert Rev. Mol. Diagn. 6(2), 129-131 (2006).
103. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5), 1331-1346 (2001). • Concise analysis of personalized treatment.
104. Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. NY Acad. Sci. 1030, 69-77 (2004).
105. Owens RJ, Young RJ. The genetic engineering of monoclonal antibodies. J. Immunol. Methods 168(2), 149-165 (1994).
106. Shitara K, Kuwana Y, Nakamura K et al. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunol. Immunother. 36(6), 373-380 (1993).
107. LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. Sci. USA 86(11), 4220-4224 (1989).
108. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000).
109. Azria D, Bibeau F, Barbier N et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on locoregional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 5, 62 (2005).
110. EGFR PharmDx™ package insert (manual use) www.dakousa.com/ prod_downloadpackageinsert.pdf?objectid=108136005
111. EGFR PharmDx™ package insert (automated use) www.dakousa.com/ prod_downloadpackageinsert.pdf?objectid=108133004